Tatemichi Satoshi, Kobayashi Kumi, Maezawa Ayaka, Kobayashi Mamoru, Yamazaki Yoshinobu, Shibata Nobuo
Pharmacology Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., Azumino City, Japan.
Yakugaku Zasshi. 2006 Mar;126 Spec no.:209-16. doi: 10.1248/yakushi.126.209.
The selectivity of silodosin (KMD-3213), an antagonist of alpha(1)-adrenoceptor (AR), to the subtypes (alpha(1A)-, alpha(1B)- and alpha(1D)-ARs) was examined by a receptor-binding study and a functional pharmacological study, and we compared its subtype-selectivity with those of other alpha(1)-AR antagonists. In the receptor-binding study, a replacement experiment using [(3)H]-prazosin was conducted using the membrane fraction of mouse-derived LM (tk-) cells in which each of three human alpha(1)-AR subtypes was expressed. In the functional pharmacological study, the following isolated tissues were used as representative organs with high distribution densities of alpha(1)-AR subtypes (alpha(1A)-AR: rabbit prostate, urethra and bladder trigone; alpha(1B)-AR: rat spleen; alpha(1D)-AR: rat thoracic aorta). Using the Magnus method, we studied the inhibitory effect of silodosin on noradrenaline-induced contraction, and compared it with those of tamsulosin hydrochloride, naftopidil and prazosin hydrochloride. Silodosin showed higher selectivity for the alpha(1A)-AR subtype than tamsulosin hydrochloride, naftopidil or prazosin hydrochloride (affinity was highest for tamsulosin hydrochloride, followed by silodosin, prazosin hydrochloride and naftopidil in that order). Silodosin strongly antagonized noradrenaline-induced contractions in rabbit lower urinary tract tissues (including prostate, urethra and bladder trigone, with pA(2) or pKb values of 9.60, 8.71 and 9.35, respectively). On the other hand, the pA(2) values for antagonism of noradrenaline-induced contractions in rat isolated spleen and rat isolated thoracic aorta were 7.15 and 7.88, respectively. Selectivity for lower urinary tract was higher for silodosin than for the other alpha(1)-AR antagonists. Our data suggest that silodosin has a high selectivity for the alpha(1A)-AR subtype and for the lower urinary tract.
通过受体结合研究和功能药理学研究,考察了α1肾上腺素能受体(AR)拮抗剂西洛多辛(KMD-3213)对各亚型(α1A-、α1B-和α1D-AR)的选择性,并将其亚型选择性与其他α1-AR拮抗剂进行了比较。在受体结合研究中,使用表达三种人α1-AR亚型中每一种的小鼠源性LM(tk-)细胞的膜组分,进行了用[3H]哌唑嗪的置换实验。在功能药理学研究中,以下分离组织被用作具有高α1-AR亚型分布密度的代表性器官(α1A-AR:兔前列腺、尿道和膀胱三角区;α1B-AR:大鼠脾脏;α1D-AR:大鼠胸主动脉)。使用马格努斯方法,研究了西洛多辛对去甲肾上腺素诱导的收缩的抑制作用,并将其与盐酸坦索罗辛、萘哌地尔和盐酸哌唑嗪的抑制作用进行了比较。西洛多辛对α1A-AR亚型的选择性高于盐酸坦索罗辛、萘哌地尔或盐酸哌唑嗪(亲和力对盐酸坦索罗辛最高,其次依次为西洛多辛、盐酸哌唑嗪和萘哌地尔)。西洛多辛强烈拮抗去甲肾上腺素诱导的兔下尿路组织收缩(包括前列腺、尿道和膀胱三角区,pA2或pKb值分别为9.60、8.71和9.35)。另一方面,西洛多辛对大鼠离体脾脏和大鼠离体胸主动脉中去甲肾上腺素诱导的收缩的拮抗作用的pA2值分别为7.15和7.88。西洛多辛对下尿路的选择性高于其他α1-AR拮抗剂。我们的数据表明,西洛多辛对α1A-AR亚型和下尿路具有高选择性。